Get the Stockscreener App
4.39
1.35%
-0.06
After Hours:
4.37
-0.02
-0.46%
Scynexis Inc stock is traded at $4.39, with a volume of 31,615.
It is down -1.35% in the last 24 hours and down -15.41% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$4.45
Open:
$4.582
24h Volume:
31,615
Relative Volume:
0.24
Market Cap:
$43.68M
Revenue:
$20.34M
Net Income/Loss:
$-24.52M
P/E Ratio:
-1.2276
EPS:
-3.5761
Net Cash Flow:
$-5.92M
1W Performance:
-1.57%
1M Performance:
-15.41%
6M Performance:
-37.70%
1Y Performance:
-49.19%
1-Day Range:
$4.3662
$4.582
1-Week Range:
$4.27
$5.00
52-Week Range:
$3.53
$9.12
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
4.39 | 43.68M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
SCYNEXIS Appoints Nephrology Veteran Steven K. Burke to Board of Directors - Minichart
SCYNEXIS adds veteran biopharma leader to board - TipRanks
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - The Manila Times
SCYNEXIS, Inc. (SCYX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Scynexis appoints Todd Minga as senior VP of R&D By Investing.com - Investing.com Australia
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
Scynexis names Sanjay Subramanian as chief financial officer - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Form 8K Scynexis Inc For: 10 September By Investing.com - Investing.com Nigeria
SCYNEXIS, Inc. Announces Executive Changes, Effective September 9, 2026 - marketscreener.com
SCYX Looks 72.0% Undervalued on GF Value™ but Remains a Possible Value Trap - GuruFocus
SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026 - marketscreener.com
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline - citybiz
SCYNEXIS Names Sanjay Subramanian as CFO - marketscreener.com
Scynexis names Sanjay Subramanian as chief financial officer By Investing.com - Investing.com India
SCYNEXIS appoints new CFO amid leadership transition - TipRanks
Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer - TradingView
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer - marketscreener.com
A new finance chief brings 20 years of experience to SCYNEXIS - Stock Titan
Scynexis Appoints New CFO Amid Transition - Intellectia AI
Scynexis Inc (SCYX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SCYNEXIS Inc. (SCYX) Advances 1.92% to $5.32 as Stock Holds Above Key $5.05 SupportDiamond Pattern - vinanet.vn
Scynexis Inc (SCYX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SCYNEXIS, Inc. (SCYX) latest stock news and headlines - Yahoo Finance Australia
SCYNEXIS to Participate in Upcoming Investor Conferences - The Manila Times
SCYX Q2 2026 Earnings: EPS Soars to $0.63, Crushing Consensus by 221.9%Earnings Season Preview - dars.gov.et
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Press Release: SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
SCYNEXIS (SCYX) Market: Moves 3.60% Up to $5.33; Boundary Watch: the Near-Term Reference Band Stretches From $5.06 to $5.60 under the Current SnapshotShort Setup Alerts - vinanet.vn
SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen - MarketBeat
SCYX Q1 2026 Earnings: Deep EPS Miss and Missing Revenue Put Pipeline Execution in FocusEstimate Dispersion - vinanet.vn
SCYNEXIS (SCYX) investors CVI and Heights disclose 5.9% ownership stake - Stock Titan
Revenue per share of SCYNEXIS, Inc. – DUS:135 - TradingView
Free cash flow per share of SCYNEXIS, Inc. – DUS:135 - TradingView
SCYNEXIS, Inc. Earnings and Revenue – DUS:135 - TradingView
135 Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXIS, Inc.: Fundamental Analysis and Financial Ratings | 135 | US8112923094 - marketscreener.com
Great Point Partners (SCYX) reports 9.99% beneficial stake in Scynexis - Stock Titan
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):